Dopaminergic syndromes of sleep, mood and mentation: Evidence from Parkinson's disease and related disorders

Sleep and Hypnosis

Volumn 4, Issue 4, 2002, Pages 119-131

  McNamara, Patrick ^a   Durso, Raymon ^a   Auerbach, Sanford ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Depression; Dopamine; Dreams; Narcolepsy; Parkinson's disease; REM sleep; REM sleep behavior disorder

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; METHAMPHETAMINE; MODAFINIL; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; VANOXERINE;

AFFECT; AMYGDALOID NUCLEUS; COGNITION; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC ACTIVITY; DREAM; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; FRONTAL LOBE; HUMAN; MOOD; MOOD DISORDER; NARCOLEPSY; NONHUMAN; PARASOMNIA; PARKINSON DISEASE; PERSEVERATION; PERSONALITY; PREFRONTAL CORTEX; REM SLEEP; REVIEW; SLEEP; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; THINKING; THOUGHT DISORDER; UNPLEASANT DREAM; VIVID DREAM;

EID: 0036961610     PISSN: 13021192     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Maquet P, Franck G. REM sleep and the amygdala. Molecular Psychiatry 1997;2:195-196.
2. Braun AR, Balkin TJ, Wesenten NJ, Carson RE, Varga M, Baldwin P, Selbie S, Belenki G, Herscovitch P. Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)0 PET study. Brain 1997;120:1173-1197.
3. Nofzinger EA, Mintun MA, Wiseman MB, Kupfer DJ, Moore RY. Forebrain activation in REM sleep: An FDG PET study. Brain Research 1997;770:192-201.
4. Hobson JA, Stickgold R, Pace-Schott EF. The neuropsychology of REM sleep dreaming. Neuroreport 1998;9:R1-14.
5. Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Research Online 1998;1:49-61.
6. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. Journal of Neuroscience 2001;21:1787-94.
7. Agid Y, Javoy-Agid M, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. New York: Buttersworth & Co. 1987;166-230.
8. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease? Neurology 1980;30:1326-1330.
9. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of the cortical dopamine and neuroadrenaline seratonin and their metabolites in Parkinson's disease. Brain Research 1983;275:321-328.
10. Shinotoh H, Calne D. The use of PET in Parkinson's disease. Brain & Cognition 1995;28:297-310.
11. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Archives of Neurology 1988;45:497-501.
12. German D, Manaye K, Smith W, Woodward D, Saper C. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Annals of Neurology 1989;26:507-514.
13. Rinne JO, Rummukainen J, Palijarvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Annals of Neurology 1989;26:47-50.
14. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
15. Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain 1988;11:323-345.
16. Brown RG, Marsden CD. An investigation of the phenomenon of 'set' in Parkinson's disease. Movement Disorders 1988;3:152-161.
17. Caltagirone C, Carlesimo A, Nocentini U, Vicari S. Defective concept formation in Parkinsonian's is independent from mental deterioration. Journal of Neurology, Neurosurgery, and Psychiatry 1989;52:334-337.
18. Caltagirone C, Carlesimo A, Nocentini U, Vicari S. Differential aspects of cognitive impairment in patients suffering from Parkinson's and Alzheimer's disease: A neurophysiological evaluation. International Journal of Neuroscience 1989;44:1-7.
19. Pirozzolo FJ, Hansch EC, Mortimer JA, Webster DD, Kuskowski MA. Dementia in Parkinson's disease: A neuropsychological analysis. Brain and Cognition 1982;1:71-83.
20. Hietanen M, Teravainen H. Cognitive performance in early Parkinson's disease. Acta Neurologica Scandinavica 1986;73:151-159.
21. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease: The cortical focus of neostriatal overflow. Brain 1986;109:845-883.
22. Cools AR, Van Den Brecken JH, Horstink MW, Van Spaendonck KP, Berger HJ. Cognitive and motor shifting aptitude disorder in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 1984;47:443-453.
23. Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease. Neurology 1986;36:1179-1185.
24. Downes JJ, Sharp HM, Costall BM, Sagar HJ, Howe J. Alternating fluency in Parkinson's disease. An evaluation of the attentional control theory of cognitive impairment. Brain 1993;116:887-902.
25. Gotham A, Brown R, Marsden C. 'Frontal' cognitive functioning in patients with Parkinson's disease 'on' and 'off' levadopa. Brain 1988;11:311-321.
26. Lange KW, Paul GM, Naumann M, Gesell W. Dopaminergic effects on cognitive performance in patients with Parkinson's disease. Journal of Neural Transmission 1995;(Suppl.)46:423-432.
27. Starkstein SE, Merello M. Psychiatric and Cognitive Disorders in Parkinson's Disease. Cambridge: Cambridge University Press, 2002.
28. Lange KW, Paul GM, Robbins TW, Marsden CD. L-Dopa and frontal cognitive function in Parkinson's disease. In: Narabayashi H, Nagatsu T, Scheltens P, eds. Advances in Neurology New York: Raven Press, Ltd. 1993;60:475-478.
29. Hubble JP, Koller WC. The parkinsonian personality. Advances in Neurology 1995;65:43-48.
30. Cipolli C, Bolzani R, Massetani R, Murri L, Muratorio A. Dream structure in Parkinson's patients. Journal of Nervous Mental Disorders 1992;180:516-523.
31. Aldrich MS. Parkinsonism. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine (3rd ed.). Philadelphia: W.B. Saunders 2000;1051-1057.
32. Jankovic J. Emerging view of dopamine in modulating sleep/wake state from and unlikely source: PD. Neurology 2002;58:341-346.
33. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57:1392-1396.
34. Ulivelli M, Rossi S, Lombardi C, Bartalini S, Rocchi R, Giannini F, Passero S, Battistini N, Lugaresi E. Polysomnographic characterization of pergolide induced sleep attacks in idiopathic PD. Neurology 2002;58:462-465.
35. Tan EK, Lum SY, Fook-Chong SMC. Evaluation of somnolence in Parkinson's disease: Comparison with age and sex matched controls. Neurology 2002;58:465-468.
36. Arnulf I, Konofal E, Merino-Andreu M, et al. Clinical profiles of somnolence on Parkinson's disease. Neurology (in press).
37. Jouvet M. Cataplexie et sommeil paradoxical reflexes. Comptes Rendus des Seances de La Societe de Biologie et de Ses Filiales 1964;159:83-87.
38. Jouvet M. The Paradox of Sleep: The Story of Dreaming. MIT Press, 1999.
39. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: Demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.
40. Albin RL, Koeppe RA, Chervin RS, Consens FB, Wernette K, Frey KA, Aldrich MS. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000;55:1410-1412.
41. Ferman TJ, Boeve BF, Smith GE, Silber MH, Kokmen E, Petersen RC, Ivnik RJ. REM sleep behavior disorder and dementia: Cognitive differences when compared with AD. Neurology 1999;52:951-957.
42. Shirakawa S, Takeuchi N, Uchimura N, Ohyama T, Maeda H, Abe T, Ishibashi M, Ohshima Y, Ohshima H. Study of image findings in rapid eye movement sleep behavioral disorder. Psychiatry Clinical Neuroscience 2002;53:291-292.
43. Schenck CH, Mahowald MW. Polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep disorder (RBD); Sustained clonazepam efficacy in 89.5% of 57 treated patients. Cleveland Clinical Journal of Medicine 1990;57(Suppl):s9-s23.
44. Mahowald MW, Schenck CH. REM sleep parasomnias. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine (3rd ed.). Philadelphia: W.B. Saunders 2000;724-741.
45. Hublin C, Launes J, Nikkinen P, Partinen M. Dopamine D2 receptors in human narcolepsy: A SPECT study with 123I-IBZM. Acta Neurologica Scandinavia 1994;90:186-189.
46. McFarlane JG, List SJ, Moldofsky H, Firnau G, Chen JJ, Szechtman H, Garnett S, Nahmias C. Dopamine D2 receptors quantified in vivo in human narcolepsy. Biological Psychiatry 1997;41:305-310.
47. Rinne JO, Hublin C, Partinen M, Ruottinen H, Nagren K, Lehikoinen P, Ruotsalainen U, Laihinen A. Striatal dopamine D1 receptors in narcolepsy: A PET study with [11C]NNC 756. Journal of Sleep Research 1996;5:262-264.
48. Kaufman C, Schuld A, Pullmacher T, Auer DP. Reduced cortical gray matter in narcolepsy: Preliminary findings with voxel-based morphometry. Neurology 2002;58:1852-1855.
49. Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. Journal of Sleep Research 2001;10:75-81.
50. Kryger MH, Walid R, Manfreda J. Diagnosis received by narcolepsy patients prior to diagnosis by a sleep specialist. Sleep 2002;25:36-41.
51. Lee JH, Bliwise DL, Lebret-Bories E, Guilleminault C, Dement WC. Dream-disturbed sleep in insomnia and narcolepsy. Journal Nervous Mental Disorders 1993;181:320-324.
52. Guilleminault C, Anagnos A. Narcolepsy. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine (3rd ed.). Philadelphia: W.B. Saunders, 2000;676-686.
53. Duffy JD, Coffey CE. The neurobiology of depression. In: Trimble MR, Cummings JL, eds. Contemporary Behavioral Neurology. New York: Butterworth-Heinemann, 1997;275-288.
54. Honig A, Van Praag HM. Depression: Neurobiological, Psychopathological, and Therapeutic Advances. New York: Wiley, 1997.
55. Koob GF. Neural mechanisms of drug reinforcement. Annals of the New York Academy of Science 1992;654:171-191.
56. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychology Review 1987;94:469-492.
57. Schultz W, Romo R, Ljungberg T, Mirenowicz J, Hollerman J, Dickson A. Reward-related signals carried by dopamine neurons. In: Houk J, Davis J, Beiser D, eds. Models of Information Processing in the Basal Ganglia. Cambridge, MA: MIT Press, 1995;233-248.
58. Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS. CSF amine metabolites in depression. Biological Psychiatry 1992;31:112-118.
59. Anand A, Charney DS. Catecholamines in depression. In: Honig A, van Praag HM, eds. Depression: Neurobiological, Psychopathological and Therapeutic Advances. New York: Wiley, 1997;147-178.
60. Elliot R. The neuropsychological profile in unipolar depression. Trends in Cognitive Science 1998;2:447-454.
61. Rogers MA, Bradshaw JL, Pantelis CK, Philips JG. Frontostriatal deficits in unipolar major depression. Brain Research Bulletin 1998;47:297-310.
62. Baxter LR Jr, Schwartz JM, Phelps ME et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Archives of General Psychiatry 1989;46:243-250.
63. Drevets WC. Functional Neuroimaging studies of depression. The anatomy of melancholia. Annual Review of Medicine 1998;49:341-361.
64. Robinson RG, Travella JI. Neuropsychiatry of mood disorders. In: Fogel BS, Schiffer RB, Rao SM, eds. Neuropsychiatry. Baltimore: Williams & Wilkins, 1996;287-305.
65. Cartwright RD. Dreaming in sleep-disordered patients. In: Chokroverty S, ed. Sleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects. (2nd Edition) Woburn, MA: Butterworth-Heinemann 1999;127-134.
66. Benca R. Mood disorders. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine (3rd ed.). Philadelphia: W.B. Saunders, 2000;1140-1157.
67. Morrison AR, Sanford LD, Ross RJ. Initiation of REM sleep: Beyond the brain stem. In: Malick BN, Inoue S, eds. Rapid Eye Movement Sleep, 1999.
68. Calvo JM, Simon-Arcel K, Fernandez-Mas R. Prolonged enhancement of REM sleep produced by carbachol microinjection into the amygdala. Neuroreport 1996;7:577-580.
69. Sanford LD, Ross RJ, Tejani-Butt SM, Morrison AR. Amygdaloid control of alerting and behavioral arousal in rats: Involvement of seratonergic mechanisms. Archives of Italian Biology 1995;134:81-89.
70. Aggleton JP, Saunders RC. The amygdala - What's happened in the last decade? In: Aggleton JP, ed. The Amygdala. A Functional Analysis. Oxford: Oxford University Press, 2000;1-31.
71. Sadikot AF, Parent A. The monoaminergic innervation of the amygdala in the squirrel monkey: An immunohistochemical study. Neuroscience 1990;36:431-447.
72. Haber SN, Fudge JL. The interface between dopamine neurons and the amygdala: Implications for schizophrenia. Schizophrenia Bulletin 1997;23:471-482.
73. Davis M. The role of the amygdala in conditioned and unconditioned fear and anxiety. In: Aggleton JP, ed. The Amygdala. A Functional Analysis. Oxford: Oxford University Press 2000;213-288.